Intellia Therapeutics Secures $400 Million Term Loan for Gene Editing Treatments
News provided byIntellia Therapeutics, Inc · 2 min read
CAMBRIDGE, Mass., Sept. 04, 2026 /CourierPR/ -- Intellia Therapeutics, a leading biopharmaceutical company leveraging CRISPR gene editing technology, has secured a significant financial boost through a non-dilutive debt facility. The company entered into a $400 million senior secured term loan with OrbiMed, a global healthcare investment firm, to bolster its financial and operational capabilities as it advances its pipeline of innovative treatments.
The agreement includes an initial $75 million term loan, which was funded at the closing. An additional $225 million can be drawn in five tranches, contingent upon Intellia achieving specified milestones related to its lead product, lonvoguran ziclumeran (lonvo-z). An extra $100 million is also available, subject to mutual agreement between the parties during the five-year term of the loan agreement.
“Lonvo-z has the potential to transform the treatment paradigm for individuals with hereditary angioedema (HAE),” said Edward Dulac, Intellia’s Chief Financial Officer. “This non-dilutive financing will enable us to more freely execute our strategic plan to launch lonvo-z in the U.S. and advance our other programs, including nexiguran ziclumeran (nex-z), through critical milestones.”
OrbiMed, a recognized leader in the in vivo gene editing sector, is pleased to support Intellia’s mission. “We are excited to partner with Intellia as it approaches several important milestones, including the anticipated approval and commercial launch of lonvo-z,” said Matthew Rizzo, a General Partner at OrbiMed.
Lonvo-z is an in vivo CRISPR gene editing candidate designed to inactivate the kallikrein B1 (KLKB1) gene, aiming to provide a one-time treatment for HAE. The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), as well as the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).
“Intellia Therapeutics is at the forefront of gene editing technology, with a strong pipeline of potential curative treatments,” said Rizzo. “We believe this collaboration will be instrumental in advancing their programs and creating value for both shareholders and patients.”
Intellia’s other programs include nexiguran ziclumeran (nex-z), which is being developed for transthyretin amyloidosis, a rare, progressive disease. The company is also working on early-stage pipeline development efforts that could significantly impact the treatment landscape for severe diseases.
TD Cowen served as the exclusive financial advisor to Intellia on this transaction, while Goodwin Procter LLP and Covington & Burling LLP provided legal advice to Intellia and OrbiMed, respectively.
The financial and operational support from OrbiMed will help Intellia navigate upcoming regulatory and commercialization milestones, including the anticipated U.S. approval and launch of lonvo-z, which could offer a transformative treatment for HAE patients.